For a succinct analysis of 1H 2024 venture investment and exit activity in life sciences and health care, take a look at HSBC’s Venture Healthcare Report, Shake it off: HSBC Innovation Banking Analysis, 1H 2024. Lead author Jonathan Norris and his team analyze early stage, venture deals, private M&A and IPO activity in Healthtech, Med Device, Biopharma, and Dx/Tools, in both the United States and Europe. The Report also provides a deep dive into growth and investment in computational biology.
Several key findings of the Report are:
- 1H 2024 investments in Healthtech reversed the 2023 decline with deal activity rising each quarter. The sector also experienced a surge in earlier-stage deals.
- Med device investments are reported to remain stable in large part to an increase in first-financing deals and dollars in 2Q 2024. An increase in early-stage investments in deals requiring robust clinical trials, particularly in neurology.
- For Biopharma, the Report highlights exists and a strong M&A market for growth in the sector. Investment in Biopharma reportedly increased by 35%, and there were 51 private deals exceeding $100 million.
- Dx/Tools sector experienced a decline in first-financing deals. A resurgence of growth investors for companies reaching commercialization provided a bright spot for this sector. Early-stage valuations are reported to remain strong but companies with “lofty” valuations from 2020-2021 experienced down or flat rounds.
The Report summarizes that 1H 2024 experienced increased investment across every analyzed sector with numerous investor-led financings. IPO interest increased in Biopharma as well as high deal-value private M&A.
Author(s)
Related Insights
August 18, 2026
PTAB Trial Insights
Navigating IPR Discretionary Denial White Waters with Examiner Error: A Practitioner's Guide
Decided five years before the surge of discretionary denial decisions in 2025, the second prong of Advanced Bionics requires the Director to determine “whether the petitioner has demonstrated that the Office erred in a manner material to the patentability of challenged claims” when the same or substantially the same art or arguments previously were presented to the Office.
August 17, 2026
Foley Viewpoints
Recent SAT Publications on Fraudulent CFDIs – Immediate Risks for Your Business
The Tax Administration Service (SAT) continues to audit taxpayers as part of the new expedited domiciliary audit procedure, through which it can determine whether the digital tax invoices (CFDI) issued by such taxpayers are fraudulent.
August 17, 2026
Health Care Law Today
FQHCs: The Expanding Landscape of Medicare Billing Outside of PPS for Care Management Services
Federally Qualified Health Centers (FQHCs) are primarily reimbursed by Medicare through the Prospective Payment System (PPS), which pays a per-visit rate to cover a typical bundle of medically necessary services provided during a patient encounter. Increasingly, however, FQHCs have opportunities to bill certain care management services to Medicare outside the PPS bundle. The steady expansion of these services over the last decade is one of the most significant changes to Medicare FQHC reimbursement since the Affordable Care Act (ACA).